BOLT · Bolt Biotherapeutics, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that this raises substantial doubt about its ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-18 | Yonehiro Grant |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
6,850 |
| 2026-09-18 | Quinn William P. |
Director, President, CEO and CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
9,132 |
| 2026-09-18 | Nemec Sarah |
Senior VP, Finance and PAO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
4,077 |
| 2026-09-17 | Yonehiro Grant |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
4,909 |
| 2026-09-17 | Nemec Sarah |
Senior VP, Finance and PAO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,922 |
| 2026-09-17 | Quinn William P. |
Director, President, CEO and CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
6,545 |
| 2026-09-16 | Nemec Sarah |
Senior VP, Finance and PAO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
843 |
| 2026-09-16 | Quinn William P. |
Director, President, CEO and CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
1,889 |
| 2026-09-16 | Yonehiro Grant |
Chief Operating Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Common Stock
|
1,417 |
| 2026-06-10 | ONETTO NICOLE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-10 | Berner Laura |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-10 | Dupont Jakob |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-10 | LAPORTE KATHLEEN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-10 | O'CALLAGHAN BRIAN |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Stock Option (Right to Buy)
|
5,000 |
| 2026-06-05 | Quinn William P. |
Director, President, CEO and CFO |
Buy↑
Filing footnotes — Common Stock (Direct)
These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). |
Common Stock
|
637 |
| 2026-06-05 | Nemec Sarah |
Senior VP, Finance and PAO |
Buy↑
Filing footnotes — Common Stock (Direct)
These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). |
Common Stock
|
509 |
| 2026-01-28 | Yonehiro Grant |
Chief Operating Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. |
Employee Stock Option (Right to Buy)
|
10,000 |
| 2026-01-28 | Nemec Sarah |
Senior VP, Finance and PAO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. |
Employee Stock Option (Right to Buy)
|
8,000 |
| 2026-01-28 | Quinn William P. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. |
Employee Stock Option (Right to Buy)
|
20,000 |
| 2025-12-12 | Quinn William P. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. |
Employee Stock Option (Right to Buy)
|
21,999 |
| 2025-12-12 | Dupont Jakob |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
849 |
| 2025-12-12 | LAPORTE KATHLEEN |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,250 |
| 2025-12-12 | O'CALLAGHAN BRIAN |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,810 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
3,214 |
| 2025-12-12 | Nemec Sarah |
Senior VP, Finance and PAO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. |
Employee Stock Option (Right to Buy)
|
2,499 |
| 2025-12-12 | O'CALLAGHAN BRIAN |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Director Stock Option (Right to Buy)
|
1,100 |
| 2025-12-12 | Quinn William P. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. |
Employee Stock Option (Right to Buy)
|
34,999 |
| 2025-12-12 | LAPORTE KATHLEEN |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Director Stock Option (Right to Buy)
|
1,100 |
| 2025-12-12 | Berner Laura |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
613 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. |
Employee Stock Option (Right to Buy)
|
17,499 |
| 2025-12-12 | Nemec Sarah |
Senior VP, Finance and PAO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
2,199 |
| 2025-12-12 | ONETTO NICOLE |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,393 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. |
Employee Stock Option (Right to Buy)
|
7,749 |
| 2025-12-12 | LAPORTE KATHLEEN |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,250 |
| 2025-12-12 | Nemec Sarah |
Senior VP, Finance and PAO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
2,199 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
1,653 |
| 2025-12-12 | Nemec Sarah |
Senior VP, Finance and PAO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
1,236 |
| 2025-12-12 | Nemec Sarah |
Senior VP, Finance and PAO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on December 22, 2021, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
600 |
| 2025-12-12 | Quinn William P. |
Director, President, CEO and CFO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. |
Employee Stock Option (Right to Buy)
|
11,749 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. |
Employee Stock Option (Right to Buy)
|
11,749 |
| 2025-12-12 | ONETTO NICOLE |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,100 |
| 2025-12-12 | LAPORTE KATHLEEN |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,250 |
| 2025-12-12 | Quinn William P. |
Director, President, CEO and CFO |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
10,499 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Other↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
660 |
| 2025-12-12 | ONETTO NICOLE |
Director |
Award↑
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Director Stock Option (Right to Buy)
|
1,100 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
660 |
| 2025-12-12 | Yonehiro Grant |
Chief Operating Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
4,999 |
| 2025-12-12 | O'CALLAGHAN BRIAN |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,250 |
| 2025-12-12 | LAPORTE KATHLEEN |
Director |
Other↓
Filing footnotes — Director Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Director Stock Option (Right to Buy)
|
1,250 |
| 2025-12-12 | Quinn William P. |
Director, President, CEO and CFO |
Award↑
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. |
Employee Stock Option (Right to Buy)
|
10,499 |